Core Viewpoint - Chengdu's biopharmaceutical industry is experiencing rapid growth, positioning itself as a leading hub for innovation in the sector, prompting discussions on how to capitalize on this momentum and attract more high-caliber pharmaceutical companies [1][2]. Group 1: Industry Growth and Opportunities - The biopharmaceutical sector is witnessing an explosion of high-growth sub-sectors, with potential areas for development including nuclear medicine, where Chengdu has existing advantages and emerging representative companies [2][3]. - The integration of AI with biopharmaceuticals is seen as a potential avenue for disruptive innovation, with local resources in both AI and pharmaceuticals being leveraged to explore this intersection [2][3]. Group 2: Medical Device Sector Development - Chengdu is addressing its shortcomings in the medical device sector, with the establishment of a comprehensive service platform for medical devices and CDMO projects, which will enhance local testing capabilities [3]. - The medical device industry in China has significant growth potential, with a current "drug-device ratio" of 4:1 compared to 1:1 in Western countries, indicating room for expansion [3]. Group 3: Ecosystem and Structural Challenges - Chengdu's pharmaceutical ecosystem is nearly complete but lacks a top-tier production base among the national top 500 companies, which is essential for a full industrial chain [4]. - There are calls for a more robust ecosystem that supports continuous innovation in pharmaceuticals, emphasizing the need for systemic reforms to facilitate the establishment of international pharmaceutical companies [5][6]. Group 4: Policy and Regulatory Environment - The efficiency of regulatory processes is crucial for attracting pharmaceutical companies, as seen in the example of a large pharmaceutical firm choosing Suzhou due to streamlined customs processes [6]. - Improving policy details and regulatory frameworks could enable Chengdu to attract key enterprises more rapidly than other cities, enhancing its competitive edge in the biopharmaceutical landscape [6].

Core Viewpoint - Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (referred to as "Xiantong Pharmaceutical") has submitted an application for an IPO on the Hong Kong Stock Exchange, drawing attention back to the nuclear medicine sector [1] Group 1: Company Overview - Xiantong Pharmaceutical is one of the earliest companies in China engaged in the research and development of nuclear medicine, focusing on innovative radioactive drugs since 2014 [2] - The company has a pipeline that includes 15 assets targeting oncology, neurodegenerative diseases, and cardiovascular diseases, with core products including XTR008, XTR006, XTR004, and XTR003 [2][3] Group 2: Product Details - XTR008 is a radioligand targeting somatostatin receptors for treating neuroendocrine tumors, currently in the registration phase [3] - XTR006 is a PET diagnostic radioligand for suspected Alzheimer's disease, while XTR004 is used for PET myocardial perfusion imaging [3] - Xiantong Pharmaceutical's diagnostic nuclear medicine, fluorine-18 beta-phenyl injection (marketed as Ouweining), has been approved, along with adenosine injection (marketed as Oudal) for assisting in diagnosing myocardial ischemia [3] Group 3: Market Potential - The global nuclear medicine market is projected to grow from $5 billion in 2018 to $9.7 billion in 2024, with a compound annual growth rate (CAGR) of 11.7%, and is expected to reach $57.3 billion by 2035, with a CAGR of 17.5% from 2024 to 2035 [4] Group 4: Funding and Financials - Xiantong Pharmaceutical has raised over 2.9 billion yuan through nine rounds of financing since 2017, with a post-investment valuation of 5.188 billion yuan [4] - The net proceeds from the IPO will primarily be used for R&D of core products, development of other candidates, enhancing sales and marketing capabilities, and establishing a new production base in the Beijing-Tianjin-Hebei region [5][6] Group 5: Revenue Sources - The company is currently in a research investment phase, with revenues of 10.232 million yuan in 2023 and 44.064 million yuan in 2024, alongside net losses of 309 million yuan and 156 million yuan respectively [7] - The main source of income is from external licensing, accounting for 31% and 15% of total revenue in 2023 and 2024, respectively, while CRO/CDMO services are expected to become the primary revenue source in 2024 [7] Group 6: Market Challenges - The approved PET tracer Ouweining will only be available for sale starting January 2025, and the company has established partnerships with about 50 medical institutions in key regions [8] - The production and delivery of nuclear medicine are time-sensitive, with a shelf life of only 10 hours for Ouweining, necessitating a robust production network [8]

Core Viewpoint - Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (referred to as "Xiantong Pharmaceutical") has officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) for an IPO, aiming to become the first listed company in the radioactive drug sector in Hong Kong [1][3] Financial Performance - For the fiscal years ending December 31, 2023, and 2024, Xiantong Pharmaceutical reported revenues of approximately RMB 10.23 million and RMB 44.06 million, respectively, with net losses of about RMB 309.23 million and RMB 156.12 million [2][5] - The company anticipates significant operating losses and expenses in the coming years as it advances its clinical research and seeks regulatory approvals for its candidate products [5][6] Product Pipeline and Market Position - Xiantong Pharmaceutical is a leader in China's radioactive drug market, focusing on the development and commercialization of innovative radioactive drugs, with a pipeline that includes 15 assets targeting oncology, neurodegenerative diseases, and cardiovascular diseases [3][4] - The company has launched two products: XTR005, the first approved PET tracer targeting Aβ in China, and adenosine injection [4] Research and Development - R&D expenditures for 2023 and 2024 are projected at RMB 296.99 million and RMB 227.98 million, respectively, with core product development costs accounting for a significant portion of these expenses [7] - The company emphasizes the need for specialized knowledge and qualifications in various fields to develop radioactive drugs, indicating a commitment to building a professional team to meet these requirements [7][8] Industry Outlook - The global radioactive drug market is expected to grow from USD 9.7 billion in 2024 to USD 57.3 billion by 2035, with a compound annual growth rate (CAGR) of 17.5% [6] - The radioactive drug sector is gaining attention due to its potential for precise diagnosis and treatment, attracting continuous investment despite inherent challenges [6][8]

Core Viewpoint - The recent advancements in innovative nuclear medicine products by the company, particularly the Yttrium-90 microsphere injection, have garnered significant international recognition, showcasing the clinical potential of its nuclear medicine pipeline [1][4][9]. Group 1: Product Developments - The innovative nuclear medicine product, Yttrium-90 microsphere injection, has been highlighted at major international conferences, indicating its clinical value and potential in treating liver cancer [4][5]. - The company has successfully launched a global innovative ophthalmic drug for treating demodex blepharitis, which is expected to enhance its market presence in the Greater Bay Area and mainland China [3][9]. - The Yttrium-90 microsphere injection has achieved a disease control rate of 90.9% and an objective response rate of 87.8% in clinical studies, establishing it as a leading treatment for hepatocellular carcinoma (HCC) [7][8]. Group 2: Financial Performance - The company's stock price has surged over 50% since early May, reaching a historical high of 9.19 HKD, with a year-to-date increase of over 130% [3]. - The Yttrium-90 microsphere injection has treated nearly 2,000 patients and is projected to generate approximately 500 million HKD in sales revenue for 2024, reflecting a year-on-year growth rate exceeding 140% [7][8]. Group 3: Research and Clinical Impact - The Yttrium-90 microsphere injection has become a focal point in global HCC treatment, with multiple studies presented at the ASCO and APPLE conferences [5][6]. - The company has trained over 1,100 doctors across 70 hospitals to enhance the clinical application of its products, indicating a commitment to improving treatment accessibility [8][9]. Group 4: Infrastructure and Future Plans - The company is establishing a "zero-radiation" intelligent nuclear medicine factory in Chengdu, which will serve as a comprehensive platform for research, production, and sales, enhancing its operational capabilities [13][16]. - The factory is set to be the first of its kind globally, with a planned investment exceeding 3 billion RMB, focusing on isotope production and automated manufacturing processes [16][18].

今日（5.21）A股和H股创新药/生物科技板块延续涨势，可T+0交易的恒生生物科技ETF（513280）涨超2%，生物药ETF （159839）涨超1%。 消息面上，国产双抗再迎"天价"大单。三生国健、三生制药双双公告，与辉瑞就PD-1/VEGF双特异性抗体SSGJ-707订立协 议，辉瑞将获得该产品在全球（不包括中国内地）的权益。本次交易价格为12.5亿美元的首付款及最多48亿美元的潜在里程碑 付款，并收取两位数百分比的特许权使用费。此外，辉瑞还将认购三生制药价值1亿美元的普通股股份。创造了国内药企 License Out金额最高纪录！ | ટસે | ા રસ્સ્રે | 300 = | 综合屏 F9 前复权 超级叠加 画线 工具 © 2 > | 恒年生物科技ETF ① | | 513280 | | --- | --- | --- | --- | --- | --- | --- | | 初科技ETF] | | 2025/05/21 收 0.922 幅 2.22%(0.020) 开 0.904 高 0.923 | 低0.897 均 | 0.922 | | +0.020 +2.22% | | | | 0.8 ...

Investment Rating - The report initiates coverage on the company with a "Buy" rating and sets a target price of HKD 10.15, based on a 17x PE for 2025 [1][8][6]. Core Viewpoints - The company is positioned as a significant player in China's nuclear medicine industry, with a diversified portfolio across pharmaceutical technology, biotechnology, nuclear medicine, and cardiovascular precision intervention [1][5]. - The traditional business segments are expected to maintain steady growth, providing a solid foundation for future development [1][5]. - The nuclear medicine segment is anticipated to experience rapid revenue growth from 2025 to 2027, driven by the commercialization of Y90 microspheres and a robust pipeline of differentiated products focused on integrated tumor diagnosis and treatment [2][20]. Summary by Sections Nuclear Medicine - The company has a unique position in the nuclear medicine market with commercialized products and a differentiated pipeline. Revenue from this segment is expected to grow rapidly from 2025 to 2027, with Y90 microspheres projected to peak at over HKD 3 billion in sales [2][20]. - The low penetration rate of Y90 microspheres presents significant growth potential, supported by hospital access, new indications, and potential insurance coverage [2][21]. Pharmaceutical Technology - The pharmaceutical technology segment is projected to achieve a CAGR of approximately 7% from 2025 to 2027, driven by strong demand for exclusive products in respiratory and cardiovascular categories [3][21]. - The segment is expected to remain stable despite short-term fluctuations due to centralized procurement, with new acquisitions and self-research initiatives supporting growth [3][21]. Biotechnology - The biotechnology segment is expected to maintain steady revenue growth, benefiting from a leading market share in taurine and cysteine, with a nearly 50% global market share in taurine as of 2023 [4][21]. - The segment's performance is supported by stable market demand and the company's strong position in the amino acid market [4][21]. Financial Projections - The company forecasts a net profit of HKD 2.12 billion, HKD 2.33 billion, and HKD 2.68 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year changes of -14%, +10%, and +15% [6][7]. - Revenue is expected to reach HKD 12.65 billion in 2025, with a growth rate of 8.63% year-on-year [7][6].

Core Viewpoint - The company, YuanDa Pharmaceutical, has achieved significant milestones in the development of its global nuclear medicine R&D and production base in Chengdu, which is set to become the world's first "zero-radiation" intelligent nuclear medicine factory, marking a strategic leap in the nuclear medicine industry [1][4][11]. Group 1: Company Developments - YuanDa Pharmaceutical's Chengdu base has received a Class A Radiation Safety License from the Ministry of Ecology and Environment, with operations expected to commence in June 2025 [1][11]. - The construction of the base has set a record in the industry, completing the main structure in just five months, and is recognized for its high level of automation and comprehensive range of isotopes [1][4]. - The company has seen its stock price rise significantly, reaching a historical high of HKD 8.95, a nearly 126% increase from its low point this year, with a market capitalization exceeding HKD 30 billion [3]. Group 2: Technological Innovations - The Chengdu base features a state-of-the-art cyclotron from Belgium's IBA, enabling the independent production of critical isotopes, addressing the domestic shortage of imported isotopes [5]. - The facility employs fully automated production processes, enhancing production stability and efficiency, and significantly reducing the production cycle by approximately 80% [7]. - A comprehensive radiation monitoring system has been integrated, ensuring compliance with international safety standards and establishing a new benchmark for safety in the nuclear medicine industry [9][12]. Group 3: Market Position and Growth - The global nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 18% from 2022 to 2028, reaching approximately USD 18.7 billion, while China's market is expected to grow at a CAGR of 27% from 2023 to 2030, reaching around RMB 26 billion [12]. - YuanDa Pharmaceutical has established a complete industrial chain in the nuclear medicine sector, with a product pipeline that includes 15 innovative products targeting various cancers [12][15]. - The company is positioned as a leader in the nuclear medicine field, with the most extensive product pipeline and integrated treatment solutions, enhancing its competitive edge in the market [16][17].

Industry Overview - The nuclear medicine market is experiencing robust growth due to increasing health awareness and rapid advancements in medical technology [1] - As of July 4, 2024, 88 radioactive new drugs have been approved globally, with only 18 for treatment purposes [1] - From 2021 onwards, China's policies have strongly supported the nuclear medicine industry, which is expected to drive its development [1] - According to Ping An Securities, the nuclear medicine market in China is projected to grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6% from 2023 to 2030 [1] Company Highlights - Yuan Da Pharmaceutical (00512) is a notable player in the nuclear medicine sector, with a successful Phase II clinical trial for its global innovative product STC3141 [2] - CICC maintains profit forecasts for Yuan Da Pharmaceutical at 2.131 billion yuan for 2025 and 2.235 billion yuan for 2026 [2] - The company has received approval for its innovative drug ITM-11 to conduct Phase III clinical trials, targeting neuroendocrine tumors [3] - China Tongyuan (01763) is a leading enterprise in the nuclear medicine industry, dominating the market for radioactive pharmaceuticals and being the largest supplier of radiation source products in China [4] - In October 2023, China Tongyuan began mass production of a new dual-spiral CT radiation therapy platform, marking a significant advancement in domestic high-end radiation therapy products [4]

Core Insights - Fosun Pharma reported a revenue of 41.067 billion yuan in 2024, a slight decrease of 0.80% year-on-year, while net profit attributable to shareholders increased by 16.08% to 2.770 billion yuan [1][2] - The company achieved a net cash flow from operating activities of 4.477 billion yuan, reflecting a significant increase of 31.13% compared to the previous year, indicating improved free cash flow to support strategic transformation and R&D investments [2][3] Financial Performance - Revenue: 41.067 billion yuan in 2024, down from 41.400 billion yuan in 2023, a decrease of 0.80% [2] - Net Profit: 2.770 billion yuan in 2024, up from 2.386 billion yuan in 2023, an increase of 16.08% [1][2] - Net Profit (excluding non-recurring items): 2.314 billion yuan, a rise of 15.10% from 2.011 billion yuan in 2023 [2] - Basic Earnings per Share: 1.04 yuan [1] Business Segmentation - Pharmaceutical Revenue: 28.924 billion yuan, a decline of 4.29% year-on-year; key products like Hanquyou® (trastuzumab) saw global sales of 2.810 billion yuan, an increase of 11% [3] - Medical Devices and Diagnostics Revenue: 4.323 billion yuan, down 1.53% due to decreased demand for COVID-19 products [3] - Healthcare Services Revenue: 7.647 billion yuan, an increase of 14.61% driven by specialized construction and smart healthcare initiatives [3] R&D and Innovation - R&D Investment: 5.554 billion yuan, accounting for 13.52% of revenue; seven innovative drugs/biosimilars were approved for market [3] - Notable Approvals: Slulizumab received EU approval, and HLX14 (biosimilar to dezuizumab) is under review in the US and EU [3] - Collaboration: The company is exploring new directions in nuclear medicine and gene therapy through partnerships with industry funds [3] Shareholder Returns - Proposed Dividend: The company plans to distribute a cash dividend of 3.20 yuan per 10 shares (tax included) [3]